Targeted Liquid Chromatography Multi- Reflecting Time-of-Flight Mass Spectrometry for Comprehensive Metabolic Profiling

Targeted Liquid Chromatography Multi‑Reflecting Time‑of‑Flight Mass Spectrometry for Comprehensive Metabolic Profiling — Summary

Importance of the topic

The reliable quantification of metabolites in complex biological matrices is central to clinical research, biomarker validation, and mechanistic studies of disease. Targeted assays require both high sensitivity to detect low‑abundance compounds and high specificity to distinguish analytes from matrix interferences. Advances in high‑resolution mass spectrometry (HRMS), specifically multi‑reflecting time‑of‑flight (MRT) analyzers operated in Tof MRM mode with an enhanced duty cycle (EDC), promise to combine the selectivity typical of MRM workflows with the mass accuracy and resolving power of HRMS, enabling deeper and more flexible targeted metabolic profiling on a single platform.

Objectives and study overview

This application note demonstrates a targeted Tof MRM workflow using the Xevo MRT P10 Mass Spectrometer for quantitative monitoring of approximately 61 metabolites across diverse chemical classes in urine. The study aims to:

• Evaluate sensitivity, linearity and precision of MRT‑based Tof MRM for a multi‑analyte panel.
• Illustrate method development steps including transition selection, collision energy optimization and retention time scheduling.
• Compare analytical specificity benefits gained from HRMS high resolution/accurate mass detection versus nominal mass tandem quadrupole MRM.

Methodology

Sample preparation: A uniformly 13C‑labeled yeast metabolite extract (U‑13C) was used to prepare a working internal standard (WIS). Pooled commercial urine samples were adjusted to different specific gravities (SG) by dilution or lyophilization and then mixed with WIS at 25 µL sample to 75 µL WIS. Samples were vortexed, chilled centrifuged and supernatant transferred for LC‑MS analysis.

Method development: Initial DDA and DIA scouting experiments identified candidate product ions and confirmed fragment identities (MS1 and MS2). Approximately 61 metabolites were targeted (36 in positive mode, 25 in negative mode). Dwell times were optimized to collect ~8–10 points per chromatographic peak. Quadrupole isolation was set to unit resolution (1 Da); product ions were acquired in high‑resolution mode with ±25 ppm tolerance. Collision energies were optimized per transition to maximize fragment intensity.

Chromatography: ACQUITY Premier UPLC system with Atlantis Premier BEH Z‑HILIC column (1.7 µm, 2.1 x 150 mm). Column at 40 °C, sample tray 6 °C, injection volume 2 µL, flow 0.35 mL/min. Mobile phases contained aqueous/acetonitrile mixtures with 10 mM ammonium acetate; a gradient was used to provide good retention and peak shape for polar metabolites.

Mass spectrometry: Xevo MRT P10 Mass Spectrometer operated in Tof MRM acquisition with Enhanced Duty Cycle (EDC) to synchronize ion trapping/release with the Tof pusher frequency. Ionization: electrospray in positive and negative modes. Typical settings included capillary voltage ~2 kV, desolvation temperature 500 °C, desolvation gas 800 L/hr, cone gas 50 L/hr, dual‑point lock mass for accurate calibration. Data acquisition and peak integration employed waters_connect with the MS Quan Application using 1/x or 1/x2 calibration weighting.

Used instrumentation

• Xevo MRT P10 Mass Spectrometer (MRT Tof with EDC, dual ES+ / ES- capability)
• ACQUITY Premier UPLC System
• Atlantis Premier BEH Z‑HILIC Column, 1.7 µm, 2.1 x 150 mm
• waters_connect Software Platform with MS Quan Application for acquisition and quantitative processing
• U‑13C labeled yeast metabolite extract used as internal standard

Results and discussion

Panel coverage and transition selection: The targeted panel spanned amino acids, organic acids, nucleotides and other polar metabolites. MS1/MS2 scouting provided high‑confidence fragment ions (observed fragment mass accuracy <2 ppm) used to build Tof MRM transitions. Tight retention time windows (±30 s) were feasible due to chromatographic stability.

Sensitivity and quantitative performance: The instrument demonstrated high sensitivity and fast acquisition, enabling short dwell times while monitoring many transitions in a single injection. For the majority of analytes the assay showed excellent linearity and precision: 48 compounds met typical acceptance criteria (coefficient of determination R2 ≥ 0.90) with calibration standards showing %CV ≤ 20% (and ≤ 25% at the LLOQ). Representative metabolites achieved signal‑to‑noise ratios >20 at the lowest calibration levels, indicating robust LLOQ performance in urine matrix across a tested SG range.

Specificity advantages: HRMS resolving power and accurate mass detection improved discrimination of target fragments from matrix interferences versus nominal‑mass QqQ MRM, leading to enhanced signal‑to‑noise and confidence in identifications. The EDC approach increased duty cycle and sensitivity by synchronizing ion trapping and release with Tof timing, allowing multiplexed monitoring without compromising data density across chromatographic peaks.

Data processing and throughput: waters_connect + MS Quan enabled automated integration, weighted calibration curve fitting and rapid review of chromatograms across all samples. The workflow supports targeted quantification with scalable throughput and facilitates review of multi‑analyte panels.

Benefits and practical applications

• High sensitivity and multiplexing: EDC‑enabled Tof MRM yields sensitivity sufficient for low‑level metabolites while accommodating large panels in a single run.
• Improved selectivity: High resolution/accurate mass fragments reduce false positives and matrix interferences common in urine and other complex matrices.
• Analytical flexibility: Platform supports both targeted quantitative and untargeted discovery workflows without instrument changeover.
• Streamlined quantification: Integrated software simplifies calibration, integration and batch review for targeted metabolomics projects.
• Relevant applications: clinical biomarker validation, translational metabolomics, pharmacometabolomics, and studies requiring combined targeted/untargeted strategies.

Future trends and potential applications

Building on these results, foreseeable developments include:

• Greater adoption of HRMS‑based targeted quantification in clinical and regulated laboratories as high‑resolution instruments demonstrate comparable quantitative performance to QqQ systems.
• Expanded isotope dilution panels (U‑13C/U‑15N) for improved absolute quantification and correction of matrix effects.
• Higher multiplexing enabled by further duty cycle and data handling improvements, allowing larger panels without loss of points/peak.
• Integration with automated sample prep and standardized reference materials to support multi‑site studies and clinical translation.
• Machine learning assisted transition selection and data quality control to accelerate panel development and reduce manual review.

Conclusion

The Xevo MRT P10 operated in Tof MRM mode with Enhanced Duty Cycle demonstrates that MRT‑based HRMS can deliver sensitive, specific and precise targeted metabolic quantification in complex biological matrices such as urine. This approach merges the selectivity and throughput advantages of MRM workflows with the mass accuracy and resolving power of HRMS, enabling flexible workflows that support both targeted quantification and untargeted discovery on a single platform. The method is well suited for clinical and translational metabolomics where broad coverage, analytical confidence and robust quantitation are required.

References

1. Nagana Gowda, G.A.; Djukovic, D. Overview of Mass Spectrometry‑Based Metabolomics: Opportunities and Challenges. Methods Mol. Biol. 2014, 1198, 3–12.
2. Verenchikov, et al. A Novel Compact Multi‑Reflecting Time‑of‑Flight Mass Spectrometer. Journal of the American Society for Mass Spectrometry 2026, 37(3), 601–611.
3. Tomcyzk, N.; Wallace, A.; Richardson, K.; Grzyb, A.; Wildgoose, J. Targeted High Resolution Quantification with Tof‑MRM and HD‑MRM. Application Brief, Waters Corporation, 2013.
4. Dorrani, M.; et al. Olaris Global Panel (OGP): A Highly Accurate and Reproducible Triple Quadrupole Mass Spectrometry‑Based Metabolomics Method for Clinical Biomarker Discovery. Metabolites. 2024, 14(5), 280.